Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- RSV-19 RSVF 6HB ?RSHZ IgG-1 Kappa SB 209763 SB209763
- Product Overview:
Respiratory syncytial virus (RSV) fusion (F) protein is a surface glycoprotein encoded by the F gene in RSV RNA.{67138} It is synthesized as an inactive precursor protein, F0, that undergoes proteolytic cleavage to release the F1 and F2 subunits, which are joined together by two disulfide bonds.{67139} Mature RSV F protein is composed of an N-terminal fusion peptide (FP), two heptad repeats (HRs), a transmembrane domain, and a cytoplasmic tail and assembles into homotrimers on the virus surface.{67138} Upon insertion of the FP in the target cell membrane, the HRs form a six-helical bundle (6-HB) that enables RSV to fuse with the target cell. RSV F protein is highly conserved between RSV subtypes A and B with approximately 90% amino acid identities.{67140} RSV is the most common causative agent of pediatric lower respiratory tract infections.{67141} Cayman’s RSV F Protein Chimeric Monoclonal Antibody was produced recombinantly from the original humanized RSHZ19 antibody sequence, substituting the mouse antigen-binding domain with the rabbit IgG1 antigen-binding domain, and can be used for ELISA and in functional assays. The RSHZ19 antibody was generated by fusing human IgG1 constant domains to the antigen-binding domain of a mouse anti-RSV F protein monoclonal antibody.{44025}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.